Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

M A Calderon, P Demoly, T Casale, C A Akdis, C Bachert, M Bewick, B M Bilò, B Bohle, S Bonini, A Bush, D P Caimmi, G W Canonica, V Cardona, A M Chiriac, L Cox, A Custovic, F De Blay, P Devillier, A Didier, G Di LorenzoG Du Toit, S R Durham, P Eng, A Fiocchi, A T Fox, R Gerth van Wijk, R M Gomez, T Haathela, S Halken, P W Hellings, L Jacobsen, J Just, L K Tanno, J Kleine-Tebbe, L Klimek, E F Knol, P Kuna, D E Larenas-Linnemann, A Linneberg, M Matricardi, H J Malling, R Moesges, J Mullol, A Muraro, N Papadopoulos, G Passalacqua, E Pastorello, O Pfaar, D Price, P Rodriguez Del Rio, R Ruëff, B Samolinski, G K Scadding, G Senti, M H Shamji, A Sheikh, J C Sisul, D Sole, G J Sturm, A Tabar, R Van Ree, M T Ventura, C Vidal, E M Varga, M Worm, T Zuberbier, J Bousquet

Research output: Contribution to journalArticle

16 Citations (Scopus)
4 Downloads (Pure)

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Original languageEnglish
Article number41
JournalClinical and Translational Allergy
Volume6
DOIs
Publication statusPublished - 23 Nov 2016

Fingerprint

Immunologic Desensitization
Life Cycle Stages
Immunotherapy
Hypersensitivity
Chronic Disease
Research
Preschool Children
Therapeutics

Keywords

  • allergen immunotherapy
  • EIA on AHA
  • AIRWAYS ICPs
  • rhinitis
  • asthma
  • ageing

Cite this

Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project. / Calderon, M A; Demoly, P; Casale, T; Akdis, C A; Bachert, C; Bewick, M; Bilò, B M; Bohle, B; Bonini, S; Bush, A; Caimmi, D P; Canonica, G W; Cardona, V; Chiriac, A M; Cox, L; Custovic, A; De Blay, F; Devillier, P; Didier, A; Di Lorenzo, G; Du Toit, G; Durham, S R; Eng, P; Fiocchi, A; Fox, A T; van Wijk, R Gerth; Gomez, R M; Haathela, T; Halken, S; Hellings, P W; Jacobsen, L; Just, J; Tanno, L K; Kleine-Tebbe, J; Klimek, L; Knol, E F; Kuna, P; Larenas-Linnemann, D E; Linneberg, A; Matricardi, M; Malling, H J; Moesges, R; Mullol, J; Muraro, A; Papadopoulos, N; Passalacqua, G; Pastorello, E; Pfaar, O; Price, D; Del Rio, P Rodriguez; Ruëff, R; Samolinski, B; Scadding, G K; Senti, G; Shamji, M H; Sheikh, A; Sisul, J C; Sole, D; Sturm, G J; Tabar, A; Van Ree, R; Ventura, M T; Vidal, C; Varga, E M; Worm, M; Zuberbier, T; Bousquet, J.

In: Clinical and Translational Allergy, Vol. 6, 41, 23.11.2016.

Research output: Contribution to journalArticle

Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilò, BM, Bohle, B, Bonini, S, Bush, A, Caimmi, DP, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, AT, van Wijk, RG, Gomez, RM, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, LK, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, DE, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, PR, Ruëff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, MH, Sheikh, A, Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, Van Ree, R, Ventura, MT, Vidal, C, Varga, EM, Worm, M, Zuberbier, T & Bousquet, J 2016, 'Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project', Clinical and Translational Allergy, vol. 6, 41. https://doi.org/10.1186/s13601-016-0131-x
Calderon, M A ; Demoly, P ; Casale, T ; Akdis, C A ; Bachert, C ; Bewick, M ; Bilò, B M ; Bohle, B ; Bonini, S ; Bush, A ; Caimmi, D P ; Canonica, G W ; Cardona, V ; Chiriac, A M ; Cox, L ; Custovic, A ; De Blay, F ; Devillier, P ; Didier, A ; Di Lorenzo, G ; Du Toit, G ; Durham, S R ; Eng, P ; Fiocchi, A ; Fox, A T ; van Wijk, R Gerth ; Gomez, R M ; Haathela, T ; Halken, S ; Hellings, P W ; Jacobsen, L ; Just, J ; Tanno, L K ; Kleine-Tebbe, J ; Klimek, L ; Knol, E F ; Kuna, P ; Larenas-Linnemann, D E ; Linneberg, A ; Matricardi, M ; Malling, H J ; Moesges, R ; Mullol, J ; Muraro, A ; Papadopoulos, N ; Passalacqua, G ; Pastorello, E ; Pfaar, O ; Price, D ; Del Rio, P Rodriguez ; Ruëff, R ; Samolinski, B ; Scadding, G K ; Senti, G ; Shamji, M H ; Sheikh, A ; Sisul, J C ; Sole, D ; Sturm, G J ; Tabar, A ; Van Ree, R ; Ventura, M T ; Vidal, C ; Varga, E M ; Worm, M ; Zuberbier, T ; Bousquet, J. / Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project. In: Clinical and Translational Allergy. 2016 ; Vol. 6.
@article{1e5f0c6520094beab5c78fc68c6561b8,
title = "Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project",
abstract = "Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sant{\'e}). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.",
keywords = "allergen immunotherapy, EIA on AHA, AIRWAYS ICPs, rhinitis, asthma, ageing",
author = "Calderon, {M A} and P Demoly and T Casale and Akdis, {C A} and C Bachert and M Bewick and Bil{\`o}, {B M} and B Bohle and S Bonini and A Bush and Caimmi, {D P} and Canonica, {G W} and V Cardona and Chiriac, {A M} and L Cox and A Custovic and {De Blay}, F and P Devillier and A Didier and {Di Lorenzo}, G and {Du Toit}, G and Durham, {S R} and P Eng and A Fiocchi and Fox, {A T} and {van Wijk}, {R Gerth} and Gomez, {R M} and T Haathela and S Halken and Hellings, {P W} and L Jacobsen and J Just and Tanno, {L K} and J Kleine-Tebbe and L Klimek and Knol, {E F} and P Kuna and Larenas-Linnemann, {D E} and A Linneberg and M Matricardi and Malling, {H J} and R Moesges and J Mullol and A Muraro and N Papadopoulos and G Passalacqua and E Pastorello and O Pfaar and D Price and {Del Rio}, {P Rodriguez} and R Ru{\"e}ff and B Samolinski and Scadding, {G K} and G Senti and Shamji, {M H} and A Sheikh and Sisul, {J C} and D Sole and Sturm, {G J} and A Tabar and {Van Ree}, R and Ventura, {M T} and C Vidal and Varga, {E M} and M Worm and T Zuberbier and J Bousquet",
note = "European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon.",
year = "2016",
month = "11",
day = "23",
doi = "10.1186/s13601-016-0131-x",
language = "English",
volume = "6",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Allergy immunotherapy across the life cycle to promote active and healthy ageing

T2 - from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

AU - Calderon, M A

AU - Demoly, P

AU - Casale, T

AU - Akdis, C A

AU - Bachert, C

AU - Bewick, M

AU - Bilò, B M

AU - Bohle, B

AU - Bonini, S

AU - Bush, A

AU - Caimmi, D P

AU - Canonica, G W

AU - Cardona, V

AU - Chiriac, A M

AU - Cox, L

AU - Custovic, A

AU - De Blay, F

AU - Devillier, P

AU - Didier, A

AU - Di Lorenzo, G

AU - Du Toit, G

AU - Durham, S R

AU - Eng, P

AU - Fiocchi, A

AU - Fox, A T

AU - van Wijk, R Gerth

AU - Gomez, R M

AU - Haathela, T

AU - Halken, S

AU - Hellings, P W

AU - Jacobsen, L

AU - Just, J

AU - Tanno, L K

AU - Kleine-Tebbe, J

AU - Klimek, L

AU - Knol, E F

AU - Kuna, P

AU - Larenas-Linnemann, D E

AU - Linneberg, A

AU - Matricardi, M

AU - Malling, H J

AU - Moesges, R

AU - Mullol, J

AU - Muraro, A

AU - Papadopoulos, N

AU - Passalacqua, G

AU - Pastorello, E

AU - Pfaar, O

AU - Price, D

AU - Del Rio, P Rodriguez

AU - Ruëff, R

AU - Samolinski, B

AU - Scadding, G K

AU - Senti, G

AU - Shamji, M H

AU - Sheikh, A

AU - Sisul, J C

AU - Sole, D

AU - Sturm, G J

AU - Tabar, A

AU - Van Ree, R

AU - Ventura, M T

AU - Vidal, C

AU - Varga, E M

AU - Worm, M

AU - Zuberbier, T

AU - Bousquet, J

N1 - European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon.

PY - 2016/11/23

Y1 - 2016/11/23

N2 - Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

AB - Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

KW - allergen immunotherapy

KW - EIA on AHA

KW - AIRWAYS ICPs

KW - rhinitis

KW - asthma

KW - ageing

U2 - 10.1186/s13601-016-0131-x

DO - 10.1186/s13601-016-0131-x

M3 - Article

C2 - 27895895

VL - 6

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

M1 - 41

ER -